Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » BGI to Receive $1.5B in 'Collaborative Funds' Over 10 Years from China Development Bank

BGI to Receive $1.5B in 'Collaborative Funds' Over 10 Years from China Development Bank

Jan 12, 2010
Premium

By Julia Karow

This article, originally posted Jan. 11, has been updated with additional information from BGI.

BGI, China's largest genome center, said last week that under a collaborative agreement it signed with the China Development Bank last month, it will receive $1.5 billion in 'collaborative funds' over the next 10 years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Robots for the Lab

Researchers have developed a robotic lab assistant, the Verge reports.

Ruling Awaited

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

To Find Where It Came From

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

Science Presents Atlas of Aberrant Cells in Lung Condition, More

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.